UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 243

Sortiert nach

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Nature communications, 2018-11, Vol.9 (1), p.4664-5, Article 4664

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence of T790M mutation in (sequential) rebiopsies in EGFR -mutated NSCLC-patients

Lung cancer (Amsterdam, Netherlands), 2014-07, Vol.85 (1), p.19-24

2014

Link zum Volltext

Verfügbarkeit prüfen

Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study

Lung cancer (Amsterdam, Netherlands), 2021-03, Vol.153, p.81-89

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular sputum analysis for the diagnosis of lung cancer

British journal of cancer, 2013-08, Vol.109 (3), p.530-537

2013

Link zum Volltext

Verfügbarkeit prüfen

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

Annals of oncology, 2017-11, Vol.28 (11), p.2725-2732

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)

Lung cancer (Amsterdam, Netherlands), 2019-04, Vol.130, p.179-186

2019

Link zum Volltext

Verfügbarkeit prüfen

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

British journal of cancer, 2016-12, Vol.115 (12), p.1504-1512

2016

Link zum Volltext

Verfügbarkeit prüfen

ES25.04 Multiple Pulmonary Lesions: Metastasis vs Multiple Primaries, From Martini's Criteria to Molecular Profiling

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S91-S92

Thunnissen, E.

2021

Link zum Volltext

Verfügbarkeit prüfen

DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach

British journal of cancer, 2015-03, Vol.112 (6), p.1105-1113

2015

Link zum Volltext

Verfügbarkeit prüfen

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

PloS one, 2017-08, Vol.12 (8), p.e0182885-e0182885

2017

Link zum Volltext

Verfügbarkeit prüfen

P06.02 Incorporating Surgical Collapse in the Pathological Assessment of Resected Adenocarcinoma in situ of the Lung. A Proof of Principle Study

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S985-S985

2021

Link zum Volltext

Verfügbarkeit prüfen

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.102-108

2019

Link zum Volltext

Verfügbarkeit prüfen

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

British journal of cancer, 2014-07, Vol.111 (2), p.413-420

2014

Link zum Volltext

Verfügbarkeit prüfen

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation

Annals of oncology, 2012-12, Vol.23 (12), p.3188-3189

2012

Link zum Volltext

Verfügbarkeit prüfen

MTE 02.01 Appropriate and Optimized Handling of Surgically Resected Specimens

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1633-S1634

Thunnissen, E.

2017

Link zum Volltext

Verfügbarkeit prüfen

Granular cell tumor of the oral cavity; a case series including a case of metachronous occurrence in the tongue and the lung

Medicina oral, patología oral y cirugía bucal, 2015-01, Vol.20 (1), p.e30-e33

2015

Link zum Volltext

Verfügbarkeit prüfen

Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii49-viii49

2018

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2016-08, Vol.98, p.118-121

2016

Link zum Volltext

Verfügbarkeit prüfen

Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.205-212

2014

Link zum Volltext

Verfügbarkeit prüfen

OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S325-S325

2018

Link zum Volltext

Verfügbarkeit prüfen

High-dose, weekly erlotinib is not an effective treatment in EGFR -mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

European journal of cancer (1990), 2014-05, Vol.50 (7), p.1399-1401

2014

Link zum Volltext

Verfügbarkeit prüfen

22O REBIOPSY IN TKI-RESISTANCE: A RETROSPECTIVE ANALYSIS

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S10-S10

2013

Link zum Volltext

Verfügbarkeit prüfen

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

The New England journal of medicine, 2020-02, Vol.382 (6), p.503-513

2020

Link zum Volltext

Verfügbarkeit prüfen

3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

European journal of cancer (1990), 2015-09, Vol.51, p.S595-S596

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 243

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink Journals - AutoHoldings

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(228)
Mit Volltextzugriff
(231)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Incidence of T790M mutation in (sequential) rebiopsies in EGFR -mutated NSCLC-patients

Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study

Molecular sputum analysis for the diagnosis of lung cancer

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

ES25.04 Multiple Pulmonary Lesions: Metastasis vs Multiple Primaries, From Martini's Criteria to Molecular Profiling

DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

P06.02 Incorporating Surgical Collapse in the Pathological Assessment of Resected Adenocarcinoma in situ of the Lung. A Proof of Principle Study

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

MTE 02.01 Appropriate and Optimized Handling of Surgically Resected Specimens

Granular cell tumor of the oral cavity; a case series including a case of metachronous occurrence in the tongue and the lung

Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)

Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma

Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC

OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study

High-dose, weekly erlotinib is not an effective treatment in EGFR -mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

22O REBIOPSY IN TKI-RESISTANCE: A RETROSPECTIVE ANALYSIS

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

Aktive Filter

Suchergebnisse filtern